Danyi Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Danyi Lu has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
- Baojian Wu
Institute of Molecular Rhythm and Metabolism, Guangzhou University of Chinese Medicine, Guangzhou 510006, China
22 shared publications Shuai Wang
Guangzhou University of Chinese Medicine
8 shared publicationsDong Dong
School of Medicine, Jinan University, Guangzhou, China
7 shared publicationsBaojian Wu
Institute of Molecular Rhythm and Metabolism, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China
5 shared publicationsTianpeng Zhang
Research Center for Biopharmaceutics and Pharmacokinetics, College of Pharmacy (T.Z., M.Z., D.L., S.W., F.Y., L.G., B.W.), and Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research (T.Z., B.W.), Jinan University, Guangzhou, China; and School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China (S.W.).
5 shared publicationsZhiguo Ma
Division of Pharmaceutics, College of Pharmacy (H.S., X.Z., D.L., Z.M., B.W.) and Guangzhou Jinan Biomedicine Research and Development Center, Jinan University, Guangzhou, China (X.W.)
5 shared publications
Latest Publications
- Open Access
- 21 October 2025
- Published by Wiley
Lysionotin enhances circadian rhythm and accelerates the recovery of DSS-induced colitis in mice by targeting the circadian clock component RORα
Background and Purpose : Circadian clock disruptions are implicated in various pathological processes, including inflammatory diseases such as ulcerative colitis (UC). Restoring or enhancing the molecular circadian clock represents a promising therapeutic strategy. Lysionotin (LYS), a natural polymethoxyflavone, was investigated for its potential role in modulating circadian rhythms and mitigating colitis. Experimental Approach : LYS was screened for circadian-amplifying effects using human U2OS cells stably expressing Per2-dLuc or Bmal1-dLuc reporters. Its interaction with RORα was assessed through luciferase reporter assays, cellular thermal shift assays (CETSA), and molecular docking. In vivo efficacy was evaluated in a DSS-induced colitis mouse model, with assessments of disease activity index (DAI), histopathology, cytokine levels, and clock gene expression. In vitro studies using LPS-stimulated DLD-1 cells further examined anti-inflammatory mechanisms and RORα dependency. Key Results : LYS significantly enhanced circadian amplitude in U2OS cells without altering periodicity. It directly bound to RORα, increased its thermostability, and activated BMAL1 transcription in a RORα-dependent manner. In DSS-induced colitis mice, LYS treatment accelerated recovery, reduced DAI scores, improved histopathology, lowered proinflammatory cytokines, and restored expression of circadian clock proteins (e.g., BMAL1, PER2, REV-ERBα). In vitro , LYS suppressed LPS-induced NF-κB activation and cytokine production via RORα. Conclusion and Implications : LYS functions as a novel RORα agonist and circadian enhancer that ameliorates experimental colitis by reinforcing circadian rhythms and suppressing NF-κB-mediated inflammation. These findings support the further development of RORα-targeting polymethoxyflavones as chronotherapeutic agents for inflammatory bowel diseases.
- 21 October 2025
- Published by Wiley
Open AccessLysionotin enhances circadian rhythm and accelerates the recovery of DSS-induced colitis in mice by targeting the circadian clock component RORα
Background and Purpose : Circadian clock disruptions are implicated in various pathological processes, including inflammatory diseases such as ulcerative colitis (UC). Restoring or enhancing the molecular circadian clock represents a promising therapeutic strategy. Lysionotin (LYS), a natural polymethoxyflavone, was investigated for its potential role in modulating circadian rhythms and mitigating colitis. Experimental Approach : LYS was screened for circadian-amplifying effects using human U2OS cells stably expressing Per2-dLuc or Bmal1-dLuc reporters. Its interaction with RORα was assessed through luciferase reporter assays, cellular thermal shift assays (CETSA), and molecular docking. In vivo efficacy was evaluated in a DSS-induced colitis mouse model, with assessments of disease activity index (DAI), histopathology, cytokine levels, and clock gene expression. In vitro studies using LPS-stimulated DLD-1 cells further examined anti-inflammatory mechanisms and RORα dependency. Key Results : LYS significantly enhanced circadian amplitude in U2OS cells without altering periodicity. It directly bound to RORα, increased its thermostability, and activated BMAL1 transcription in a RORα-dependent manner. In DSS-induced colitis mice, LYS treatment accelerated recovery, reduced DAI scores, improved histopathology, lowered proinflammatory cytokines, and restored expression of circadian clock proteins (e.g., BMAL1, PER2, REV-ERBα). In vitro , LYS suppressed LPS-induced NF-κB activation and cytokine production via RORα. Conclusion and Implications : LYS functions as a novel RORα agonist and circadian enhancer that ameliorates experimental colitis by reinforcing circadian rhythms and suppressing NF-κB-mediated inflammation. These findings support the further development of RORα-targeting polymethoxyflavones as chronotherapeutic agents for inflammatory bowel diseases.
- 9 November 2024
- Published by Elsevier in Phytomedicine
- Vol. 135, 156235
Disruption of local circadian clocks in aristolochic acid-induced nephropathy in mice
- 9 November 2024
- Published by Elsevier in Phytomedicine
- Vol. 135, 156235
Disruption of local circadian clocks in aristolochic acid-induced nephropathy in mice
- 12 March 2024
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 49 (3) , 343-353
Kinetic Characterization of Estradiol Glucuronidation by Liver Microsomes and Expressed UGT Enzymes: The Effects of Organic Solvents
Background and Objective In vitro glucuronidation of 17β-estradiol (estradiol) is often performed to assess the role of uridine 5′-diphospho-glucuronosyltransferase 1A1 (UGT1A1) in xenobiotic/drug metabolism. The objective of this study was to determine the effects of four commonly used organic solvents [i.e., dimethyl sulfoxide (DMSO), methanol, ethanol, and acetonitrile] on the glucuronidation kinetics of estradiol, which can be glucuronidated at C3 and C17 positions. Methods The impacts of organic solvents on estradiol glucuronidation were determined by using expressed UGT enzymes and liver microsomes from both human and animals. Results In human liver microsomes (HLM), methanol, ethanol, and acetonitrile significantly altered estradiol glucuronidation kinetics with increased Vmax (up to 2.6-fold) and CLmax (up to 2.8-fold) values. Altered estradiol glucuronidation in HLM was deduced to be attributed to the enhanced metabolic activities of UGT1A1 and UGT2B7, whose activities differ at the two glucuronidation positions. The effects of organic solvents on estradiol glucuronidation were glucuronidation position-, isozyme-, and solvent-specific. Furthermore, both ethanol and acetonitrile have a greater tendency to modify the glucuronidation activity of estradiol in animal liver microsomes. Conclusion Organic solvents such as methanol, ethanol, and acetonitrile showed great potential in adjusting the glucuronidation of estradiol. DMSO is the most suitable solvent due to its minimal influence on estradiol glucuronidation. Researchers should be cautious in selecting appropriate solvents to get accurate results when assessing the metabolism of a new chemical entity.
- 12 March 2024
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 49 (3) , 343-353
Kinetic Characterization of Estradiol Glucuronidation by Liver Microsomes and Expressed UGT Enzymes: The Effects of Organic Solvents
Background and Objective In vitro glucuronidation of 17β-estradiol (estradiol) is often performed to assess the role of uridine 5′-diphospho-glucuronosyltransferase 1A1 (UGT1A1) in xenobiotic/drug metabolism. The objective of this study was to determine the effects of four commonly used organic solvents [i.e., dimethyl sulfoxide (DMSO), methanol, ethanol, and acetonitrile] on the glucuronidation kinetics of estradiol, which can be glucuronidated at C3 and C17 positions. Methods The impacts of organic solvents on estradiol glucuronidation were determined by using expressed UGT enzymes and liver microsomes from both human and animals. Results In human liver microsomes (HLM), methanol, ethanol, and acetonitrile significantly altered estradiol glucuronidation kinetics with increased Vmax (up to 2.6-fold) and CLmax (up to 2.8-fold) values. Altered estradiol glucuronidation in HLM was deduced to be attributed to the enhanced metabolic activities of UGT1A1 and UGT2B7, whose activities differ at the two glucuronidation positions. The effects of organic solvents on estradiol glucuronidation were glucuronidation position-, isozyme-, and solvent-specific. Furthermore, both ethanol and acetonitrile have a greater tendency to modify the glucuronidation activity of estradiol in animal liver microsomes. Conclusion Organic solvents such as methanol, ethanol, and acetonitrile showed great potential in adjusting the glucuronidation of estradiol. DMSO is the most suitable solvent due to its minimal influence on estradiol glucuronidation. Researchers should be cautious in selecting appropriate solvents to get accurate results when assessing the metabolism of a new chemical entity.
- 4 March 2023
- Published by Taylor & Francis in Xenobiotica
- Vol. 53 (3) , 215-222
Regulation of BCRP expression and sulfasalazine pharmacokinetics by the nuclear receptor REV-ERBα
BCRP (breast cancer resistance protein) is a crucial efflux transporter involved in the regulation of the pharmacokinetics and pharmacodynamics of a wide range of drugs. Herein, we aimed to investi...
- 4 March 2023
- Published by Taylor & Francis in Xenobiotica
- Vol. 53 (3) , 215-222
Regulation of BCRP expression and sulfasalazine pharmacokinetics by the nuclear receptor REV-ERBα
BCRP (breast cancer resistance protein) is a crucial efflux transporter involved in the regulation of the pharmacokinetics and pharmacodynamics of a wide range of drugs. Herein, we aimed to investi...
- Open Access
- 22 December 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 1088294
Puerariae lobatae radix protects against UVB-induced skin aging via antagonism of REV-ERBα in mice
Puerariae lobatae radix (PLR) is a wildly used herbal medicine. Here we aimed to assess the PLR efficacy against UVB (ultraviolet-B)-induced skin aging and to determine the mechanisms thereof. We found a significant protective effect of PLR (topical application) on UVB-induced skin aging in mice, as evidenced by reduced skin wrinkles, epidermal thickness, and MDA (malondialdehyde) content as well as increased levels of HYP (hydroxyproline) and SOD (superoxide dismutase) in the skin. In the meantime, Mmp-1, p21 and p53 levels were decreased in the skin of PLR-treated mice. Anti-aging effects of PLR were also confirmed in L929 cells. Furthermore, PLR up-regulated skin expression of BMAL1, which is a known regulator of aging by promoting Nrf2 and antioxidant enzymes. Consistently, Nrf2 and several genes (i.e., Prdx6, Sod1, and Sod2) encoding antioxidant enzymes in the skin were increased in PLR-treated mice. Moreover, based on Gal4 chimeric assay, Bmal1 reporter gene and expression assays, we identified PLR as an antagonist of REV-ERBα that can increase Bmal1 expression. Intriguingly, loss of Rev-erbα protected mice against UVB-induced skin aging and abrogated the protective effect of PLR. In conclusion, PLR acts as an antagonist of REV-ERBα and promotes the expression of BMAL1 to protect against skin aging in mice.
- 22 December 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 1088294
Open AccessPuerariae lobatae radix protects against UVB-induced skin aging via antagonism of REV-ERBα in mice
Puerariae lobatae radix (PLR) is a wildly used herbal medicine. Here we aimed to assess the PLR efficacy against UVB (ultraviolet-B)-induced skin aging and to determine the mechanisms thereof. We found a significant protective effect of PLR (topical application) on UVB-induced skin aging in mice, as evidenced by reduced skin wrinkles, epidermal thickness, and MDA (malondialdehyde) content as well as increased levels of HYP (hydroxyproline) and SOD (superoxide dismutase) in the skin. In the meantime, Mmp-1, p21 and p53 levels were decreased in the skin of PLR-treated mice. Anti-aging effects of PLR were also confirmed in L929 cells. Furthermore, PLR up-regulated skin expression of BMAL1, which is a known regulator of aging by promoting Nrf2 and antioxidant enzymes. Consistently, Nrf2 and several genes (i.e., Prdx6, Sod1, and Sod2) encoding antioxidant enzymes in the skin were increased in PLR-treated mice. Moreover, based on Gal4 chimeric assay, Bmal1 reporter gene and expression assays, we identified PLR as an antagonist of REV-ERBα that can increase Bmal1 expression. Intriguingly, loss of Rev-erbα protected mice against UVB-induced skin aging and abrogated the protective effect of PLR. In conclusion, PLR acts as an antagonist of REV-ERBα and promotes the expression of BMAL1 to protect against skin aging in mice.
- 1 January 2022
- Published by Bentham Science Publishers Ltd. in Current Drug Metabolism
- Vol. 23 (1) , 2-7
Pharmacokinetics-based Chronotherapy
Dosing time-dependency of pharmacokinetics (or chronopharmacokinetics) has been long recognized. Studies in recent years have revealed that daily rhythmicity in expression of drug-metabolizing enzymes and transporters (DMETs) are key factors determining chronopharmacokinetics. In this article, we briefly summarize current knowledge with respect to circadian mechanisms of DMETs and discuss how rhythmic DMETs are translated to drug chronoeffects. More importantly, we present our perspectives on pharmacokinetics-based chronotherapy.
- 1 January 2022
- Published by Bentham Science Publishers Ltd. in Current Drug Metabolism
- Vol. 23 (1) , 2-7
Pharmacokinetics-based Chronotherapy
Dosing time-dependency of pharmacokinetics (or chronopharmacokinetics) has been long recognized. Studies in recent years have revealed that daily rhythmicity in expression of drug-metabolizing enzymes and transporters (DMETs) are key factors determining chronopharmacokinetics. In this article, we briefly summarize current knowledge with respect to circadian mechanisms of DMETs and discuss how rhythmic DMETs are translated to drug chronoeffects. More importantly, we present our perspectives on pharmacokinetics-based chronotherapy.
- 1 November 2021
- Published by Elsevier in Biochemical Pharmacology
- Vol. 193, 114807
Involvement of REV-ERBα dysregulation and ferroptosis in aristolochic acid I-induced renal injury
- 1 November 2021
- Published by Elsevier in Biochemical Pharmacology
- Vol. 193, 114807
Involvement of REV-ERBα dysregulation and ferroptosis in aristolochic acid I-induced renal injury
- 1 September 2021
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 571, 167-173
A novel pyrrole-imidazole polyamide targets Aurora kinase A and suppresses tumor growth in vivo
- 1 September 2021
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 571, 167-173
A novel pyrrole-imidazole polyamide targets Aurora kinase A and suppresses tumor growth in vivo
- 5 August 2021
- Published by Springer Nature in Nature Nanotechnology
- Vol. 16 (10) , 1150-1160
Intrinsic bioactivity of black phosphorus nanomaterials on mitotic centrosome destabilization through suppression of PLK1 kinase
Although nanomaterials have shown promising biomedical application potential, incomplete understanding of their molecular interactions with biological systems prevents their inclusion into mainstream clinical applications. Here we show that black phosphorus (BP) nanomaterials directly affect the cell cycle’s centrosome machinery. BP destabilizes mitotic centrosomes by attenuating the cohesion of pericentriolar material and consequently leads to centrosome fragmentation within mitosis. As a result, BP-treated cells exhibit multipolar spindles and mitotic delay, and ultimately undergo apoptosis. Mechanistically, BP compromises centrosome integrity by deactivating the centrosome kinase polo-like kinase 1 (PLK1). BP directly binds to PLK1, inducing its aggregation, decreasing its cytosolic mobility and eventually restricting its recruitment to centrosomes for activation. With this mechanism, BP nanomaterials show great anticancer potential in tumour xenografted mice. Together, our study reveals a molecular mechanism for the tumoricidal properties of BP and proposes a direction for biomedical application of nanomaterials by exploring their intrinsic bioactivities.
- 5 August 2021
- Published by Springer Nature in Nature Nanotechnology
- Vol. 16 (10) , 1150-1160
Intrinsic bioactivity of black phosphorus nanomaterials on mitotic centrosome destabilization through suppression of PLK1 kinase
Although nanomaterials have shown promising biomedical application potential, incomplete understanding of their molecular interactions with biological systems prevents their inclusion into mainstream clinical applications. Here we show that black phosphorus (BP) nanomaterials directly affect the cell cycle’s centrosome machinery. BP destabilizes mitotic centrosomes by attenuating the cohesion of pericentriolar material and consequently leads to centrosome fragmentation within mitosis. As a result, BP-treated cells exhibit multipolar spindles and mitotic delay, and ultimately undergo apoptosis. Mechanistically, BP compromises centrosome integrity by deactivating the centrosome kinase polo-like kinase 1 (PLK1). BP directly binds to PLK1, inducing its aggregation, decreasing its cytosolic mobility and eventually restricting its recruitment to centrosomes for activation. With this mechanism, BP nanomaterials show great anticancer potential in tumour xenografted mice. Together, our study reveals a molecular mechanism for the tumoricidal properties of BP and proposes a direction for biomedical application of nanomaterials by exploring their intrinsic bioactivities.
- Open Access
- 14 December 2020
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 73 (3) , 398-409
Chronotoxicity of Semen Strychni is associated with circadian metabolism and transport in mice
We aimed to determine the circadian responses of mice to Semen Strychni and to investigate the role of pharmacokinetics in generating chronotoxicity. Total extract of Semen Strychni was administered by oral gavage to wild-type (WT) and Bmal1−/− (a circadian clock-deficient model) mice at different circadian time points for toxicity (including survival) and pharmacokinetic characterization. Nephrotoxicity and neurotoxicity were evaluated by measuring plasma creatinine and creatine kinase BB (CK-BB), respectively. Drug metabolism and transport assays were performed using liver/intestine microsomes and everted gut sacs, respectively. Semen Strychni nephrotoxicity and neurotoxicity as well as animal survival displayed significant circadian rhythms (the highest level of toxicity was observed at ZT18 and the lowest level at ZT2 to ZT6). According to pharmacokinetic experiments, herb dosing at ZT18 generated higher plasma concentrations (and systemic exposure) of strychnine and brucine (two toxic constituents) compared with ZT6 dosing. This was accompanied by reduced formation of both dihydroxystrychnine and strychnine glucuronide (two strychnine metabolites) at ZT18. Bmal1 ablation sensitized mice to Semen Strychni-induced toxicity (with increased levels of plasma creatinine and CK-BB) and abolished the time dependency of toxicity. Metabolism of Semen Strychni (strychnine and brucine) in the liver and intestine microsomes of WT mice was more extensive at ZT6 than at ZT18. These time differences in hepatic and intestinal metabolism were lost in Bmal1−/− mice. Additionally, the intestinal efflux transport of Semen Strychni (strychnine and brucine) was more extensive at ZT6 than ZT18 in WT mice. However, the time-varying transport difference was abolished in Bmal1−/− mice. Circadian responses of mice to Semen Strychni are associated with time-varying efflux transport and metabolism regulated by the circadian clock (Bmal1). Our findings may have implications for optimizing phytotherapy with Semen Strychni via timed delivery.
- 14 December 2020
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 73 (3) , 398-409
Open AccessChronotoxicity of Semen Strychni is associated with circadian metabolism and transport in mice
We aimed to determine the circadian responses of mice to Semen Strychni and to investigate the role of pharmacokinetics in generating chronotoxicity. Total extract of Semen Strychni was administered by oral gavage to wild-type (WT) and Bmal1−/− (a circadian clock-deficient model) mice at different circadian time points for toxicity (including survival) and pharmacokinetic characterization. Nephrotoxicity and neurotoxicity were evaluated by measuring plasma creatinine and creatine kinase BB (CK-BB), respectively. Drug metabolism and transport assays were performed using liver/intestine microsomes and everted gut sacs, respectively. Semen Strychni nephrotoxicity and neurotoxicity as well as animal survival displayed significant circadian rhythms (the highest level of toxicity was observed at ZT18 and the lowest level at ZT2 to ZT6). According to pharmacokinetic experiments, herb dosing at ZT18 generated higher plasma concentrations (and systemic exposure) of strychnine and brucine (two toxic constituents) compared with ZT6 dosing. This was accompanied by reduced formation of both dihydroxystrychnine and strychnine glucuronide (two strychnine metabolites) at ZT18. Bmal1 ablation sensitized mice to Semen Strychni-induced toxicity (with increased levels of plasma creatinine and CK-BB) and abolished the time dependency of toxicity. Metabolism of Semen Strychni (strychnine and brucine) in the liver and intestine microsomes of WT mice was more extensive at ZT6 than at ZT18. These time differences in hepatic and intestinal metabolism were lost in Bmal1−/− mice. Additionally, the intestinal efflux transport of Semen Strychni (strychnine and brucine) was more extensive at ZT6 than ZT18 in WT mice. However, the time-varying transport difference was abolished in Bmal1−/− mice. Circadian responses of mice to Semen Strychni are associated with time-varying efflux transport and metabolism regulated by the circadian clock (Bmal1). Our findings may have implications for optimizing phytotherapy with Semen Strychni via timed delivery.